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Abstract 
Review on congenital/neonatal and infant leukemias, 
with data on clinics, pathology, and involved genes. 
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Identity 
Congenital and neonatal leukemias are defined as 
those diagnosed within the first 4 weeks of life. 
Account for <1% of childhood leukemias. 
Infant leukemias are defined as those diagnosed 
within the first year of like. 
Clinics and pathology 
EPIDEMIOLOGY  
Neonatal/congenital leukemia is estimated at 1-5 
cases/million live births (~2 cases per year in the 
UK) (Roberts et al., 2018). 
Infant leukemia is estimated at ~160 cases/year (41 
cases per million) in the United States (Brown et al, 
2019). 
Infant ALL accounts for 2-5% of pediatric ALL 
cases (Pui et al., 1994). 
Infant AML accounts for 6-20% of pediatric AML. 
Data has shown that patients, diagnosed to have a 
leukaemia at age 5 mths and 2 yrs, already had a 
KMT2A/AFF1 (then MLL-AF4) fusion gene in their 
neonatal blood spots/Guthrie cards (Gale et al., 
1997). 
Infant leukaemias have been suspected to have an 
environmental component (Greaves, 1996): 
- Some of the leukaemias known to be often related 
to genotoxic exposure, such as the 11q23 leukaemias 
and the t(8;16) leukaemia, may also be found in 
infants.  
- There has been a significant increase in infant acute 
leukaemias incidence of around 2.5% per year for 15 
yrs, suggesting the presence of an environmental 
factor.  
- Studies have found an increased risk after maternal 
marijuana use and alcohol consumption. 
- Maternal exposure to dietary flavonoids during 
pregnancy may contribute to the risk of KMT2A 
rearranged leukemias. 
- Infants with leukaemia (excluding Down syndrome 
cases) have more congenital anomalies (heart 
defects, digestive tract anomalies, mental delay).  
CLINICS  
Sex ratio is balanced, both in AML and in ALL 
cases. 
Neonatal leukemias:  
 Common to have hepatosplenomegaly (~80% of 
cases), skin lesions (leukemia cutis, ~50% of cases), 
CNS involvement (~50% of cases), and/or 
hyperleukocytosis. 
 Cutaneous involvement can be the presenting 
feature and can manifest as the so-called “blueberry 
muffin baby” appearance with blue, purple, brown, 
or red nodules. 
- 2/3 of AML cases have cutaneous involvement. 
- 1/2 of ALL cases have cutaneous involvement. 
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Anemia, thrombocytopenia, and neutropenia can 
lead to increased bleeding tendency, infections, and 
failure to thrive. 
 Infiltration of the CNS can cause cranial nerve 
palsies, seizures, and papilledema. 
 Meningeal infiltration can manifest as a bulging 
fontanelle. 
Infant leukemias: 
 Many have aggressive features including high WBC 
counts, hepatosplenomegaly, frequent CNS 
involvement, and/or skin infiltrations (leukemia 
cutis). 
PATHOLOGY/CYTOGENETICS 
Neonatal leukemia - 2/3 AML; 1/3 ALL 
Infant leukemia - more likely ALL than AML 
ALL 
 11q23 (KMT2A) gene rearrangements in 70-80% of 
infants and up to 91% of those infants younger than 
6 months (Pieters et al., 2007; Zweidler-McKay and 
Hilden, 2008). 
 Most common KMT2A partners are AFF1, MLLT1, 
MLLT3, and MLLT10 (Pieters et al., 2007). 
 Usually express CD19, CD22, and TdT by flow 
cytometry.  Those without KMT2A fusions usually 
express CD10; those with KMT2A rearrangements 
often lack CD10 but express CD15.  
AML 
 Usually myelomonocytic (FAB M4), 
monoblastic/monocytic (FAB M5), or 
megakaryoblastic leukemia (FAB M7). 
 11q23 (KMT2A) gene rearrangements in 50% of 
infants (Brown et al., 2019; Zweidler-McKay and 
Hilden, 2008). 
 Most common KMT2A partners are MLLT3, 
MLLT10, and ELL (Pieters et al., 2007) 
 Usually express CD13 and CD33 by flow 
cytometry; M4 and M5 also express CD14 and 
CD15; M7 also expresses CD61, CD42b, and/or 
CD41 by flow cytometry. 
TREATMENT  
 ALL Interfant-99 protocol uses a 7-day prednisone 
prophase and then a hybrid regimen of standard ALL 
therapy with some AML therapy elements (including 
cytarabine) (Brown et al., 2019; Pieters et al., 2007).  
 AML Generally treated on the same clinical 
protocols as older children with multiagent 




 4yr event free survival is 47% and 4-year overall 
survival is 55.3% (Pieters et al., 2007). 
- However, 4-year EFS of those with KMT2A 
rearrangements was 37% compared to 74% in those 
without KMT2A rearrangements. 
 High WBC (>300 K/uL), young age (<6 months), 
presence of KMT2A rearrangement, and poor 
prednisone response were significant predictors of 
poor outcome (Pieters et al., 2007). 
 Survival after relapse is low, with 3-year overall 
survival after relapse of 20.9% (Driessen et al., 
2016). 
 In those who relapse, outcome is negatively 
impacted by age at original diagnosis (<6 months of 
age), higher WBC count at diagnosis, and relapse 
within 1 year after diagnosis (Driessen et al., 2016). 
 In those with congenital leukemia, the 2-year EFS 
and OS is 20% (van der Linden et al., 2009).  
 AML  
 Outcomes are similar in infants to those of older 
children with 5-year overall survival of 51% and 5-
year event free survival of 44%. 
 Spontaneous regression/remission can occur in rare 
cases (Bresters et al., 2002; Roberts et al., 2018; van 
den Berg et al., 2004).  
Survivors of infant leukemia demonstrate increased 
risk of late effects including growth problems, 
learning difficulties, hypothyroidism, and pubertal 
development (Roberts et al., 2018).  
Use of hematopoietic stem cell transplantation is 
controversial and findings are not conclusive as to 
whether it improves survival. 
Disease 
Transient abnormal myelopoiesis (TAM) of 
Down syndrome 
Epidemiology 
Restricted to newborns with trisomy 21 or mosaic for 
trisomy 21. 
Clinics 
Some infants (10-25%) are asymptomatic, only 
presenting with increased circulating blasts (Massey 
et al., 2006; Klusmann et al., 2008). Most neonates 
present at 3-7 days of age with a leukocytosis and an 
abnormal platelet count (usually thrombocytopenia, 
but thrombocytosis has also been identified).  
Hepatomegaly is common due to fibrosis and/or 
megakaryoblast infiltration.  Other clinical findings 
include splenomegaly, exudative effusions 
(including pleural, pericardial, and ascites), and 
respiratory distress (due to hepatomegaly). In utero 
presentations include hydrops fetalis and anemia. 
Genes 
GATA1 somatic mutations are present. 
Evolution 
Spontaneous resolution of blasts and symptoms 
occurs in 66-84% of infants over a time period of  
2-3 months without a need for intervention 
(Klusmann et al., 2008; Gamis et al., 2011). The 
remaining infants may need supportive therapy or 
chemotherapy.  Overall, approximately 15-20% of 
cases still die, though some of these are due to other 
abnormalities associated with trisomy 21 (Klusmann 
et al., 2008; Gamis et al., 2011).  Approximately 16-
30% of infants, whether they were asymptomatic or 
had clinical symptoms, develop myeloid leukemia 
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Phenotype/cell stem origin 
Acute monoblastic/monocytic or myelomonocytic 
leukaemia (AML) or CD19+ B-cell acute 
lymphoblastic leukaemia (B-ALL). 
Epidemiology 
11q23 (KMT2A) gene rearrangements are in present 
in 70-80% of infants with B-ALL and up to 91% of 
those infants younger than 6 months with B-ALL 
(Pieters et al., 2007).  
11q23 (KMT2A) gene rearrangements are present in 
50% of infants with AML (Brown et al., 2019). 
Clinics 
Organomegaly; frequent CNS involvement; high 
WBC count (Huret et al., 1993; Johansson et al., 
1998). 
Pathology 
In those with ALL and KMT2A gene 
rearrangements, flow cytometry 
immunophenotyping often shows expression of 
CD19, CD22, TdT, and CD15 with absence of 
CD10; CD13 an CD33 may be expressed. 
In those with ALL and KMT2A gene 
rearrangements, there is often overexpression of 
FLT3. 
In those with AML, there is often expression of 
CD13, CD14, CD15, and CD33. 
Prognosis 
4 year event free survival is 37% (Pieters et al., 
2007).  
t(4;11)(q21;q23) KMT2A/AFF1: may have worse 
outcome (Heerema et al., 1994) 
Cytogenetics 
 t(4;11)(q21;q23) KMT2A/AFF1 : most common 
infant translocation; usually ALL (49% of B-ALL 
cases, and more often in those <6 months of age), but 
can be AML (<5%) (acute monoblastic/monocytic or 
myelomonocytic leukemia), or mixed phenotype 
acute leukemia (Johansson, et al., 1998). 
 
 
t(9;11)(p23;q23) KMT2A/MLLT3 : found in 22% 
infant acute monoblastic/monocytic or 
myelomonocytic AML and 17% of infant ALL 
(Köller et al., 1989; Swansbury et al., 1998). 
 t(10;11)(p12;q23) KMT2A/MLLT10 : found in 
27% infant acute monoblastic/monocytic or 
myelomonocytic AML and 5% of infant ALL 
(Lillington et al., 1998). 
 t(11;19)(q23;p13.3) KMT2A/MLLT1: found in 
22% infant ALL, mixed phenotype acute leukemia, 
and 15% acute monoblastic/monocytic or 
myelomonocytic leukemia (Huret et al., 1993; 
Moorman et al., 1998). 
 t(11;19)(q23;p13.1) KMT2A-ELL: found in 17% 
AML, usually acute myelomonocytic or 
monoblastic/monocytic leukemia (Moorman et al., 
1998). 




Phenotype/cell stem origin 
Acute megakaryoblastic leukemia (M7 AML). 
Note 
This is a cryptic fusion not identified by routine 
karyotyping, and usually requiring RNA sequencing 
for identification. 
Epidemiology 
This leukaemia is (nearly) restricted to infant cases; 
median age is 2-4 months (Bernstein et al., 1999; 
Chan et al., 1991; Lion and Haas, 1993); accounts 
for <1% AML. 
Clinics 
Organomegaly, liver and bone marrow fibrosis. 
Prognosis 
Remission is obtained in only half cases, median 
survival is 8 months (Bernstein et al., 1999). 
Disease 
AMkL with inv(16)(p13q24) CBFA2T3/GLIS2 
Phenotype/cell stem origin 
Acute megakaryoblastic leukemia in most cases, 
though rare other AML subtypes are identified with 
this fusion. 
Epidemiology 
Usually presents in infants (Bolouri et al., 2017; 
Hara et al., 2017). 
Prognosis 
Poor prognosis with 4-5-year OS ranging from 14-
41.7% and 4-5-year EFS ranging from 8-33% (de 




AML with t(11;12)(p15;p13) NUP98/KDM5A 
Phenotype/cell stem origin 
Acute megakaryoblastic leukemia in most cases, 
though rare other AML subtypes are identified with 
this fusion. 
Epidemiology 
Can present in infants (de Rooij et al., 2016). 
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Prognosis 
Usually a poor prognosis with 4-5-year OS ranging 
from 22-50% and 4-5-year EFS ranging from 22-
36% (de Rooij et al., 2013; de Rooij et al., 2016; de 
Rooij et al., 2017; Hara et al., 2017). 
Disease 
inv(16)(p13q22) 
Phenotype/cell stem origin 
Myelomonocytic leukemia (M4 AML) 
Epidemiology 
At least 3 cases reported. 
Clinics 




Phenotype/cell stem origin 
B lineage ALL 
Epidemiology 
5 known cases (Heerema et al., 1994). 
Prognosis 
unknown; CR in 5/5. 
Disease 
t(8;16)(p11;p13) KAT6A/CREBBP 
Phenotype/cell stem origin 
Acute myelomonocytic or monoblastic/monocytic 
AML. 
Clinics 
Leukemia cutis, hepatosplenomegaly. 
Prognosis 
Has shown spontaneous regression in some cases, 
though some do relapse (Dinulos et al., 1997; 
Roberts et al., 2018) Other cases require 
chemotherapy from diagnosis. 
Disease 
Juvenile myelomonocytic leukemia 
Epidemiology 
Annual incidence is approximately 0.67 
cases/million with a median age of 1.1-1.8 years and 
male to female ratio of 2-3:1. (Hasle et al.,  
1999; Niemeyer et al., 1997; Passmore et al., 2003). 
Clinics 
Splenomegaly, lymphadenopathy, and skin rashes 
are common (Hess et al., 1996).  
The diagnostic criteria for JMML are (Locatelli and 
Neimeyer, 2015; Baumann, et al., 2017).  
 Clinical and hematologic features (all 4 required) 
 Peripheral blood monocyte count ≥1 x 109/L. 
 Peripheral blood and bone marrow blast percentages 
<20%. 
 Splenomegaly. 
 No Philadelphia (Ph) chromosome or BCR/ABL1 
fusion. 
 Genetic criteria (1 finding is sufficient) 
 Somatic mutation in PTPN11, KRAS, or NRAS. 
 Clinical diagnosis of neurofibromastosis type 1 or 
NF1 mutation. 
 Germline CBL mutation and loss of heterozygosity 
of CBL. 
 Other criteria (those not meeting genetic criteria 
but having clinical and hematologic criteria must 
also have). 
 Monosomy 7 or any other chromosomal 
abnormality. 
 or ≥ 2 of the following:  
 Increased hemoglobin F (HbF) for age. 
 Myeloid or erythroid precursors on peripheral blood 
smear. 
 Granulocyte-macrophages colony-stimulating 
factor (GM-CSF) hypersensitivity in colony assay. 
 Hyperphosphorylation of STAT5. 
Prognosis 
Those with germline mutations in PTPN11, KRAS, 
NRAS, or CBL have disease that may spontaneously 
regress without therapy (Locatelli and Neimeyer, 
2015).   
However, in other cases HSCT is recommended, 
after which the 5-year overall survival rate is 64%, 
with an event free survival of 52% (Locatelli et al., 
2005). 






Encodes a histone-lysine N-methyltransferase, a 431 
kDa protein; contains 3 AT hook DNA-binding 
domains, Zinc fingers, a SET domain which is 
responsible for its DNA methyltransferase activity, 
and a bromodomain. 
Protein 
Regulates gene expression during early development 
and hematopoiesis; regulates transcription of many 
target genes, including HOX genes.  
The fusion proteins usually include the N-terminus 
AT hook and DNA methyltransferase from KMT2A 
fused to (little or most of) the partner C-term part 
from the other chromosome. 
References 
Bernstein J, Dastugue N, Haas OA, Harbott J, Heerema NA, 
Huret JL, Landman-Parker J, LeBeau MM, Leonard C, 
Mann G, Pages MP, Perot C, Pirc-Danoewinata H, 
Roitzheim B, Rubin CM, Slociak M, Viguie F. Nineteen 







Atlas Genet Cytogenet Oncol Haematol. 2020; 24(7) 282 
 
cases of the t(1;22)(p13;q13) acute megakaryblastic 
leukaemia of infants/children and a review of 39 cases: 
report from a t(1;22) study group. Leukemia. 2000 
Jan;14(1):216-8 
Chen CS, Sorensen PH, Domer PH, Reaman GH, 
Korsmeyer SJ, Heerema NA, Hammond GD, Kersey JH. 
Molecular rearrangements on chromosome 11q23 
predominate in infant acute lymphoblastic leukemia and are 
associated with specific biologic variables and poor 
outcome. Blood. 1993 May 1;81(9):2386-93 
Dinulos JG, Hawkins DS, Clark BS, Francis JS. 
Spontaneous remission of congenital leukemia. J Pediatr. 
1997 Aug;131(2):300-3 
Gale KB, Ford AM, Repp R, Borkhardt A, Keller C, Eden 
OB, Greaves MF. Backtracking leukemia to birth: 
identification of clonotypic gene fusion sequences in 
neonatal blood spots. Proc Natl Acad Sci U S A. 1997 Dec 
9;94(25):13950-4 
Greaves MF. Infant leukaemia biology, aetiology and 
treatment. Leukemia : official journal of the Leukemia 
Society of America, Leukemia Research Fund, U.K. 1996 ; 
10 (2) : 372-377. 
Heerema NA, Arthur DC, Sather H, Albo V, Feusner J, 
Lange BJ, Steinherz PG, Zeltzer P, Hammond D, Reaman 
GH. Cytogenetic features of infants less than 12 months of 
age at diagnosis of acute lymphoblastic leukemia: impact of 
the 11q23 breakpoint on outcome: a report of the Childrens 
Cancer Group. Blood. 1994 ; 83 (8) : 2274-2284. 
Huret JL, Brizard A, Slater R, Charrin C, Bertheas MF, 
Guilhot F, Hählen K, Kroes W, van Leeuwen E, Schoot EV. 
Cytogenetic heterogeneity in t(11;19) acute leukemia: 
clinical, hematological and cytogenetic analyses of 48 
patients--updated published cases and 16 new 
observations. Leukemia : official journal of the Leukemia 
Society of America, Leukemia Research Fund, U.K. 1993 ; 
7 (2) : 152-160. 
Johansson B, Moorman AV, Haas OA, Watmore AE, 
Cheung KL, Swanton S, Secker-Walker LM. Hematologic 
malignancies with t(4;11)(q21;q23)--a cytogenetic, 
morphologic, immunophenotypic and clinical study of 183 
cases. European 11q23 Workshop participants. Leukemia : 
official journal of the Leukemia Society of America, 
Leukemia Research Fund, U.K. 1998 ; 12 (5) : 779-787. 
Köller U, Haas OA, Ludwig WD, Bartram CR, Harbott J, 
Panzer-Grümayer R, Hansen-Hagge T, Ritter J, Creutzig U, 
Knapp W. Phenotypic and genotypic heterogeneity in infant 
acute leukemia. II. Acute nonlymphoblastic leukemia. 
Leukemia : official journal of the Leukemia Society of 
America, Leukemia Research Fund, U.K. 1989 ; 3 (10) : 
708-714. 
Lillington DM, Young BD, Berger R, Martineau M, Moorman 
AV, Secker-Walker LM. The t(10;11)(p12;q23) translocation 
in acute leukaemia: a cytogenetic and clinical study of 20 
patients. European 11q23 Workshop participants. 
Leukemia : official journal of the Leukemia Society of 
America, Leukemia Research Fund, U.K. 1998 ; 12 (5) : 
801-804. 
Moorman AV, Hagemeijer A, Charrin C, Rieder H, Secker-
Walker LM. The translocations, t(11;19)(q23;p13.1) and 
t(11;19)(q23;p13.3): a cytogenetic and clinical profile of 53 
patients. European 11q23 Workshop participants. 
Leukemia : official journal of the Leukemia Society of 
America, Leukemia Research Fund, U.K. 1998 ; 12 (5) : 
805-810. 
Pui CH, Behm FG, Downing JR, Hancock ML, Shurtleff SA, 
Ribeiro RC, Head DR, Mahmoud HH, Sandlund JT, Furman 
WL. 11q23/MLL rearrangement confers a poor prognosis in 
infants with acute lymphoblastic leukemia. Journal of clinical 
oncology : official journal of the American Society of Clinical 
Oncology. 1994 ; 12 (5) : 909-915. 
Pui CH, Raimondi SC, Murphy SB, Ribeiro RC, Kalwinsky 
DK, Dahl GV, Crist WM, Williams DL. An analysis of 
leukemic cell chromosomal features in infants. Blood. 1987 
; 69 (5) : 1289-1293. 
Swansbury GJ, Slater R, Bain BJ, Moorman AV, Secker-
Walker LM. Hematological malignancies with t(9;11)(p21-
22;q23)--a laboratory and clinical study of 125 cases. 
European 11q23 Workshop participants. Leukemia : official 
journal of the Leukemia Society of America, Leukemia 
Research Fund, U.K. 1998 ; 12 (5) : 792-800. 
Baumann I, Bennett JM, Neimeyer CM, Thiele J.. Juvenile 
myelomonocytic leukaemia WHO Classification of Tumours 
of Haematopoietic and Lymphoid tissues.  Editors: 
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, 
Stein H, Thiele J.  International Agency for Research on 
Cancer, Lyon, 2017. Pgs 89-92 
Bolouri H, Farrar JE, Triche T Jr, Ries RE, Lim EL, Alonzo 
TA, Ma Y, Moore R, Mungall AJ, Marra MA, Zhang J, Ma X, 
Liu Y, Liu Y, Auvil JMG, Davidsen TM, Gesuwan P, Hermida 
LC, Salhia B, Capone S, Ramsingh G, Zwaan CM, Noort S, 
Piccolo SR, Kolb EA, Gamis AS, Smith MA, Gerhard DS, 
Meshinchi S. The molecular landscape of pediatric acute 
myeloid leukemia reveals recurrent structural alterations 
and  age-specific mutational interactions Nat Med. 2018 
Jan;24(1):103-112 
Bresters D, Reus AC, Veerman AJ, van Wering ER, van der 
Does-van den Berg A, Kaspers GJ. Congenital leukaemia: 
the Dutch experience and review of the literature. Br J 
Haematol. 2002 Jun;117(3):513-24. 
Brown P, Pieters R, Biondi A. How I treat infant leukemia. 
Blood. 2019 Jan 17;133(3):205-214. 
Chan WC, Carroll A, Alvarado CS, Phillips S, Gonzalez-
Crussi F, Kurczynski E, Pappo A, Emami A, Bowman P, 
Head DR.. Acute megakaryoblastic leukemia in infants with 
t(1;22)(p13;q13) abnormality Am J Clin Pathol. 1992 
Aug;98(2):214-21 
de Rooij JD, Branstetter C, Ma J, Li Y, Walsh MP, Cheng J, 
Obulkasim A, Dang J, Easton J, Verboon LJ, Mulder HL, 
Zimmermann M, Koss C, Gupta P, Edmonson M, Rusch M, 
Lim JY, Reinhardt K, Pigazzi M, Song G, Yeoh AE, Shih LY, 
Liang DC, Halene S, Krause DS, Zhang J, Downing JR, 
Locatelli F, Reinhardt D, van den Heuvel-Eibrink MM, 
Zwaan CM, Fornerod M, Gruber TA. Pediatric non-Down 
syndrome acute megakaryoblastic leukemia is 
characterized by distinct genomic subsets with varying 
outcomes Nat Genet. 2017 Mar;49(3):451-456 
de Rooij JD, Hollink IH, Arentsen-Peters ST, van Galen JF, 
Berna Beverloo H, Baruchel A, Trka J, Reinhardt D, 
Sonneveld E, Zimmermann M, Alonzo TA, Pieters R, 
Meshinchi S, van den Heuvel-Eibrink MM, Zwaan CM. 
NUP98/JARID1A is a novel recurrent abnormality in 
pediatric acute megakaryoblastic leukemia with a distinct 
HOX gene expression pattern Leukemia. 2013 
Dec;27(12):2280-8 
de Rooij JD, Masetti R, van den Heuvel-Eibrink MM, 
Cayuela JM, Trka J,. Recurrent abnormalities can be used 
for risk group stratification in pediatric AMKL: a retrospective 
intergroup study. Blood. 2016 Jun 30;127(26):3424-30 
Driessen EM, de Lorenzo P, Campbell M, Felice M, Ferster 
A, Hann I, Vora A, Hovi L, Escherich G, Li CK, Mann G, 
Leblanc T, Locatelli F, Biondi A, Rubnitz J, Schrappe M, 
Silverman L, Stary J, Suppiah R, Szczepanski T, Valsecchi 







Atlas Genet Cytogenet Oncol Haematol. 2020; 24(7) 283 
 
M, Pieters R.. Outcome of relapsed infant acute 
lymphoblastic leukemia treated on the interfant-99 protocol. 
Leukemia. 2016 May;30(5):1184-7. 
Gamis AS, Alonzo TA, Gerbing RB, Hilden JM, Sorrell AD, 
Sharma M, Loew TW, Arceci RJ, Barnard D, Doyle J, 
Massey G, Perentesis J, Ravindranath Y, Taub J, Smith 
FO.. Natural history of transient myeloproliferative disorder 
clinically diagnosed in Down syndrome neonates: a report 
from the Children's Oncology Group Study A2971. Blood. 
2011 Dec 22;118(26):6752-9 
Hara Y, Shiba N, Ohki K, Tabuchi K, Yamato G, Park MJ, 
Tomizawa D, Kinoshita A, Shimada A, Arakawa H, Saito 
AM, Kiyokawa N, Tawa A, Horibe K, Taga T, Adachi S, Taki 
T, Hayashi Y. Prognostic impact of specific molecular 
profiles in pediatric acute megakaryoblastic leukemia in 
non-Down syndrome Genes Chromosomes Cancer. 2017 
May;56(5):394-404 
Hasle H, Aricò M, Basso G, Biondi A, Cantù Rajnoldi A, 
Creutzig U, Fenu S, Fonatsch C, Haas OA, Harbott J, 
Kardos G, Kerndrup G, Mann G, Niemeyer CM, Ptoszkova 
H, Ritter J, Slater R, Starý J, Stollmann-Gibbels B, Testi AM, 
van Wering ER, Zimmermann M. Myelodysplastic 
syndrome, juvenile myelomonocytic leukemia, and acute 
myeloid leukemia associated with complete or partial 
monosomy 7. European Working Group on MDS in 
Childhood (EWOG-MDS). Leukemia : official journal of the 
Leukemia Society of America, Leukemia Research Fund, 
U.K. 1999 ; 13 (3) : 376-385. 
Hess JL, Zutter MM, Castleberry RP, Emanuel PD. Juvenile 
chronic myelogenous leukemia. American journal of clinical 
pathology. 1996 ; 105 (2) : 238-248. 
Klusmann JH, Creutzig U, Zimmermann M, Dworzak M, 
Jorch N, Langebrake C, Pekrun A, Macakova-Reinhardt K, 
Reinhardt D.. Treatment and prognostic impact of transient 
leukemia in neonates with Down syndrome. Blood. 2008 
Mar 15;111(6):2991-8. 
Lion T, Haas OA. Acute megakaryocytic leukemia with the 
t(1;22)(p13;q13) Leuk Lymphoma. 1993 Sep;11(1-2):15-20 
Locatelli F, Niemeyer CM.. How I treat juvenile 
myelomonocytic leukemia Blood. 2015 Feb 12;125(7):1083-
90. 
Locatelli F, Nöllke P, Zecca M, Korthof E, Lanino E, Peters 
C, Pession A, Kabisch H, Uderzo C, Bonfim CS, Bader P, 
Dilloo D, Stary J, Fischer A, Révész T, Führer M, Hasle H,  
Trebo M, van den Heuvel-Eibrink MM, Fenu S, Strahm B, 
Giorgiani G, Bonora MR, Duffner U, Niemeyer CM; 
European Working Group on Childhood MDS; European 
Blood and Marrow Transplantation Group.. Hematopoietic 
stem cell transplantation (HSCT) in children with juvenile 
myelomonocytic leukemia (JMML): results of the EWOG-
MDS/EBMT trial. Blood. 2005 Jan 1;105(1):410-9. 
Massey GV, Zipursky A, Chang MN, Doyle JJ, Nasim S, 
Taub JW, Ravindranath Y, Dahl G, Weinstein HJ; Children's 
Oncology Group (COG).. A prospective study of the natural 
history of transient leukemia (TL) in neonates with Down 
syndrome (DS): Children's Oncology Group (COG) study 
POG-9481. Blood. 2006 Jun 15;107(12):4606-13. 
Niemeyer CM, Arico M, Basso G, Biondi A, Cantu Rajnoldi 
A, Creutzig U, Haas O, Harbott J, Hasle H, Kerndrup G, 
Locatelli F, Mann G, Stollmann-Gibbels B, van't Veer-
Korthof ET, van Wering E, Zimmermann M, and members 
of the European Working Group on Myelodysplastic 
Syndromes in Childhood (EWOG-MDS).. Chronic 
myelomonocytic leukemia in childhood: a retrospective 
analysis of 110 cases. Blood. 1997 May 15;89(10):3534-43. 
Passmore SJ, Chessells JM, Kempski H, Hann IM, 
Brownbill PA, Stiller CA.. Paediatric myelodysplastic 
syndromes and juvenile myelomonocytic leukaemia in the 
UK: a population-based study of incidence and survival. Br 
J Haematol. 2003 Jun;121(5):758-67 
Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, 
Felice M, Hovi L, LeBlanc T, Szczepanski T, Ferster A, 
Janka G, Rubnitz J, Silverman L, Stary J, Campbell M, Li 
CK, Mann G, Suppiah R, Biondi A, Vora A, Valsecchi MG. 
A treatment protocol for infants younger than 1 year with 
acute lymphoblastic leukaemia (Interfant-99): an 
observational study and a multicentre randomised trial. 
Lancet. 2007 Jul 21;370(9583):240-250 
Roberts I, Fordham NJ, Rao A, Bain BJ. Neonatal 
leukaemia Br J Haematol. 2018 Jul;182(2):170-184. 
van den Berg H, Hopman AH, Kraakman KC, de Jong D. 
Spontaneous remission in congenital leukemia is not 
related to (mosaic) trisomy 21: case presentation and 
literature review. Pediatr Hematol Oncol. 2004 
Mar;21(2):135-44. 
van der Linden MH, Creemers S, Pieters R.. Diagnosis and 
management of neonatal leukaemia. Semin Fetal Neonatal 
Med. 2012 Aug;17(4):192-195 
van der Linden MH, Valsecchi MG, De Lorenzo P, Möricke 
A, Janka G, Leblanc TM, Felice M, Biondi A, Campbell M, 
Hann I, Rubnitz JE, Stary J, Szczepanski T, Vora A, Ferster 
A, Hovi L, Silverman LB, Pieters R. Outcome of congenital 
acute lymphoblastic leukemia treated on the Interfant-99 
protocol Blood. 2009 Oct 29;114(18):3764-8. 
Zweidler-McKay PA, Hilden JM. The ABCs of infant 
leukemia. Curr Probl Pediatr Adolesc Health Care. 2008 
Mar;38(3):78-94 
This article should be referenced as such: 
Chisholm KM. Infant leukaemias, Congenital 
leukaemias, Neonatal leukaemias.. Atlas Genet 
Cytogenet Oncol Haematol. 2020; 24(7):278-283. 
